Dr. Linghua Wang (Linghua Wang, MD, PhD, MD Anderson Cancer Center) leads a computational biology lab, using single-cell and spatial omics to unravel tumor complexity—advancing cancer research with bioinformatics. As a leader in our Data Science TeamLab, she exemplifies #RadicalCollaboration—working

Online Now: Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics dlvr.it/TJnywK

After a long revision process, it finally feels like everything has come together into a complete story. Words can hardly express how grateful I am. I want to sincerely thank Professor Linghua Wang, MD, PhD for the unwavering support, thoughtful guidance, and constant encouragement

Thrilled to share our latest study just out in nature 😄A major milestone in our collaboration with ⁦Anirban Maitra⁩ Led by brilliant ⁦⁦⁦Guangsheng Pei⁩ ⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦Jimin Min⁩ ⁦⁦MD Anderson Cancer Center⁩ nature.com/articles/s4158…

(1/9) Thrilled and honored to share our NatureRevClinOncol comprehensive review dissecting the crosstalk between non-small-cell lung cancer (NSCLC) and its tumour microenvironment (TME), and how it drives progression & response to therapy. ➡️ nature.com/articles/s4157…

Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by David Russler-Germain, MD/PhD at #18icml International Conference on Malignant Lymphoma, now available online in Cancer Cell. #lmsm WashU Medicine MD Anderson Cancer Center. cell.com/cancer-cell/fu…

Proud to share our latest work now in Cancer Cell. In collaboration with Max Planck Institute of Biochemistry (MPIB), we map the progression from borderline ovarian tumors to low-grade serous ovarian cancer & propose a promising new therapeutic strategy. sciencedirect.com/science/articl… #LGSC #SBT

📢 Now live at ⁦nature⁩ Our team discovered that PPP2R1A mutations are linked to improved response to immunotherapy in ovarian clear cell carcinoma. ⁦Yibo⁩ ⁦Amir Jazaeri⁩ ⁦Rugang Zhang Lab⁩ ⁦⁦MD Anderson Cancer Center⁩ nature.com/articles/s4158…

Our study on the role of PPP2R1A mutations in cancer immunotherapy is online now! Thanks so much to the guidance and support from my wonderful mentors Linghua Wang, MD, PhD Amir Jazaeri , our fantastic collaborator Rugang Zhang Lab , and all the patients and their families!

Thrilled to see our work led by yunhe liu published in Cancer Cell featured by Nature Custom Media nature nature.com/articles/d4247… Huge thanks to Ian Le Guillou for the thoughtful interview, beautifully written piece Aubrey Bloom Clayton Boldt, Ph.D. MD Anderson Cancer Center for their support

Senescence in cancer dlvr.it/TM2Fjh

Thrilled to be first author of our comprehensive JAMA review on ovarian cancer! A big thanks to my Mentor, Prof. Bill Cliby, and Dr. Weroha for the great support and collaboration! JAMA

Online Now: Immune memory shapes ovarian cancer recurrence dlvr.it/TMDJbJ

A new Clinical Cancer Research study from our Targeting Minimal Residual Disease in Ovarian Cancer TeamLab, co-led by @amirjazaeri, @iamlinghua, MD Anderson Cancer Center, & Dr. Kai Wucherpfennig Dana-Farber News reveals that nearly half of ovarian cancer patients who appear cancer-free on scans still

Read the full study here: aacrjournals.org/clincancerres/…

MD Anderson researchers used spatial multi-omics to characterize minimal residual disease lesions in patients with advanced ovarian cancer, providing insights into potential targets to guide personalized treatments. Learn more: spr.ly/6016fkjPI #EndCancer

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI Chad Tang, MD & many others

What happens in the #OvarianCancer microenvironment after frontline treatment? Just published in Clinical Cancer Research, this study uses second-look laparoscopy to assess minimal residual disease. According to co-first author Yibo , PhD candidate MD Anderson Cancer Center, this approach could be

New research in Clinical Cancer Research shows the powerful clinical utility of detecting minimal residual disease in ovarian cancer patients. Co-first author and Gynecologic Oncology fellow at MD Anderson Cancer Center, and co-first author on this study, Anne Knisely, MD shares her thoughts Learn more

New #OvarianCancer study in Clinical Cancer Research. Residual disease may be invisible on scans, but not to all methods. Second-look laparoscopy and experimental blood tests can not only identify MRD, but also uncover critical insights in how to fight it, and help track the disease over time